Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v21.i3.20
62 pages

Mucosal Drug Delivery: Membranes, Methodologies, and Applications

Yifan Song
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, Lab for Drug Delivery, Newark, New Jersey, USA
Yiping Wang
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA
Rashmi Thakur
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA
Victor M. Meidan
Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow, Scotland UK
Bozena Michniak
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, Lab for Drug Delivery, Newark, New Jersey; University of South Carolina, Basic Pharmaceutical Sciences, 700 Sumter St., Columbia, SC 29208, USA

RÉSUMÉ

In recent years, extensive research into novel forms of drug delivery has suggested that mucosal approaches offer a promising therapeutic alternative, especially for systemically acting drugs. Transmucosal drug delivery offers many benefits, including noninvasive administration, convenience, rapid onset, as well as elimination of hepatic first-pass metabolism. The investigated absorptive surfaces consist of the nasal, buccal, ocular, vaginal, and rectal mucosae. Among these, the nasal and buccal routes have proved the most promising to date. The bioavailability achieved mainly depends upon the pathophysiological state of the mucosa and the properties of both the drug and delivery systems. Various agents can increase the efficacy of transmucosal drug delivery. These include cyclodextrins, bile salts, surfactants, fusidic acid derivatives, microspheres, liposomes, and bioadhesive agents.The mechanisms of action, effectiveness, and toxicity profiles of these enhancers have been investigated extensively in both animal and human models.


Articles with similar content:

Oral Delivery of Proteins: Progress and Prognostication
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 2
Fakhrul Ahsan, Mansoor A. Khan, Rakhi B. Shah
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Approaches and Opportunities in Colon-Specific Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Abraham Rubinstein
Oral Delivery of HIV-Protease Inhibitors
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 2
Barbra H. Stewart, Lilian Y. Li, David Fleisher
Sublingual Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 5
Bhaskara R. Jasti, Xiaoling Li, Tarun Goswami